Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab, Camrelizumab plus Apatinib in Advanced HCC
NCT05924997Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Started Jul 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05924997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924997.